DeutschNewstral
Article
jdsupra.com on 2017-05-19 00:37
Amgen Sues Coherus Under BPCIA After Completing Patent Dance
Related news
- Coherus Settles with AbbVie, and Sues Amgen, Over Adalimumab Biosimilarsjdsupra.com
- New BPCIA Complaint: Amgen Sues Pfizer over Proposed Filgrastim Biosimilarjdsupra.com
- Amgen Sues Hospira in Fourth Lawsuit Under the BPCIAjdsupra.com
- New BPCIA Complaint: Genentech Sues Amgen over Proposed Trastuzumab Biosimilarjdsupra.com
- New BPCIA Litigation: Amgen v. Coherus (D. Del.)jdsupra.com
- Coherus Settles with AbbVie, and Sues Amgen, Over Adalimumab Biosimilars (Updated)jdsupra.com
- BPCIA: Amgen Begins the Patent Dance With AbbViejdsupra.com
- Amgen Sues Pfizer and Hospira for Patent Infringement related to Hospira’s Filgrastim Biosimilarjdsupra.com
- BPCIA Helps Amgen Gain Dismissal of Genentech Complaintjdsupra.com
- Amgen Opposes Sandoz’s BPCIA Cert Petition and Files Conditional Cross-Petition on Patent Dancejdsupra.com
- Order in Amgen v. Sandoz Provides First Judicial Interpretations of the BPCIA Patent Dispute Resolution Provisionsjdsupra.com
- Update: Coherus’ Motion to Stay Discovery in Amgen v. Coherusjdsupra.com
- Coherus Requests Stay Of Discovery in Amgen v. Coherusjdsupra.com
- Coherus Files Responsive Appellate Brief in Amgen v. Coherus (pegfilgrastim)jdsupra.com
- Amgen v. Sandoz: The Supreme Court’s First Tussle with the BPCIAjdsupra.com
FTC sues to stop drugmaker Amgen from completing $27.8 billion dealpost-gazette.com- Amgen Sues Pfizer Over Proposed Neulasta Biosimilarjdsupra.com
- Apotex Accuses Amgen of Sham BPCIA Litigationjdsupra.com
- Amgen and AbbVie Settle Adalimumab BPCIA Litigationjdsupra.com
- Magistrate Judge Recommends Dismissal of Amgen v. Coherus (Pegfilgrastim) Suitjdsupra.com